Novo Nordisk A/S (NYSE:NVO) Shares Bought by Creative Planning

Creative Planning increased its position in Novo Nordisk A/S (NYSE:NVO) by 4.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 294,799 shares of the company’s stock after acquiring an additional 13,203 shares during the period. Creative Planning’s holdings in Novo Nordisk A/S were worth $35,102,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of NVO. 1620 Investment Advisors Inc. acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at $25,000. Gilliland Jeter Wealth Management LLC increased its stake in Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $25,000. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $25,000. Finally, Dixon Mitchell Investment Counsel Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $26,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NVO has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, October 10th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 0.1 %

Shares of Novo Nordisk A/S stock opened at $118.09 on Monday. Novo Nordisk A/S has a 12-month low of $92.94 and a 12-month high of $148.15. The firm has a market capitalization of $529.93 billion, a PE ratio of 40.44, a price-to-earnings-growth ratio of 1.56 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The stock’s fifty day moving average is $128.48 and its 200-day moving average is $131.72.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.